The short stature homeobox gene SHOX encodes a transcription factor which is important for normal limb development. In humans, SHOX deficiency has been associated with various short stature syndromes including Leri -Weill dyschondrosteosis (LWD), Langer mesomelic dysplasia and Turner syndrome as well as nonsyndromic idiopathic short stature. A common feature of these syndromes is disproportionate short stature with a particular shortening of the forearms and lower legs. In our studies employing microarray analyses and cell culture experiments, we revealed a strong positive effect of SHOX on the expression of the fibroblast growth factor receptor gene FGFR3, another well-known factor for limb development. Luciferase reporter gene assays show that SHOX activates the extended FGFR3 promoter, and results from chromatin immunoprecipitation (ChIP)-sequencing, ChIP and electrophoretic mobility shift assay experiments suggest a direct binding of SHOX to multiple upstream sequences of FGFR3. To further investigate these regulations in a cellular system for limb development, the effect of viral overexpression of Shox in limb bud derived chicken micromass cultures was tested. We found that Fgfr3 was negatively regulated by Shox, as demonstrated by quantitative real-time polymerase chain reaction and in situ hybridization. This repressive effect might explain the almost mutually exclusive expression patterns of Fgfr3 and Shox in embryonic chicken limbs. A negative regulation that occurs mainly in the mesomelic segments, a region where SHOX is known to be strongly expressed, offers a possible explanation for the phenotypes seen in patients with FGFR3 (e.g. achondroplasia) and SHOX defects (e.g. LWD). In summary, these data present a link between two frequent short stature phenotypes.
INTRODUCTION
The SHOX gene (short stature homeobox gene) resides in the pseudoautosomal region of the sex chromosomes and encodes a paired-related homeodomain transcription factor that is important during limb development. SHOX is expressed both in early embryonic limb development (1, 2) and in human fetal and childhood growth plates (3 -5) . In initial studies, SHOX haploinsufficiency was predicted to be the cause of the short stature seen in patients with Turner syndrome (6, 7) . Later on, the role of SHOX in a number of additional short stature phenotypes became evident. Today, it is known that heterozygous mutations or deletions of SHOX or SHOX regulatory regions are found in the majority of cases of Leri-Weill dyschondrosteosis (LWD) (8 -11) as well as in about 5% of patients with non-syndromic idiopathic short stature (ISS) (12) (13) (14) (15) . Homozygous loss of SHOX leads to the more severe phenotype of Langer mesomelic dysplasia (LMD) (16) . A common clinical feature in all these syndromes is a disproportionate mesomelic growth reduction in which the bones of the forearms and lower legs are particularly affected. This spatial specificity is thought to be caused by the distinct expression pattern of SHOX in this region (1) . An additional element seen in both LWD and LMD is a characteristic * To whom correspondence should be addressed at: Department of Human Molecular Genetics, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany. Tel: +49 6221565059; Fax: +49 6221565155; Email: gudrun.rappold@med.uni-heidelberg.de bone abnormality of the forearm called Madelung deformity. Both syndromes also exhibit a disorganization of the growth plate caused by the disruption of the normal parallel columnar arrangement of chondrocytes (17, 18) . Until now, the molecular mechanisms underlying these phenotypes are largely unexplained. So far, BNP is the only published transcriptional target of SHOX, but the molecular effect of this regulation remains elusive (4) .
Contrary to most human genes, SHOX has no orthologs in mouse or other rodents. Therefore, studies were carried out using chicken embryos as a model system to get a better understanding of the role of SHOX in limb development in vivo (2, 19, 20) . The chicken Shox protein exhibits 94% homology to the human variant with 100% conservation of all known functional domains, thus suggesting functional conservation of Shox between both species. This assumption is supported by experiments where overexpression of Shox in chicken embryos using the replication-competent avian leukemia virus long LTR with a splice acceptor (RCAS) retroviral expression system leads to an overgrowth of the long bones in the limbs (2) , which resembles the phenotypes found in humans with additional copies of SHOX (21, 22) .
Chicken micromass (chMM) cultures represent a simple in vitro culture system that simulates the processes occurring during endochondral ossification and limb development. In this system, cultures of mesenchymal cells that were isolated from embryonic chicken limbs spontaneously differentiate into chondrocytes and connective tissue (23, 24) . The use of the RCAS retroviral system to overexpress Shox in the differentiating cells offers a straightforward approach to study the role of Shox during limb development.
In this report, we have identified FGFR3 as a novel transcriptional target of SHOX and subsequently analyzed the corresponding regulatory mechanism. We further examined the regulatory role of Shox in chMM cultures and compared the effect with the human phenotypes associated with both genes.
RESULTS

SHOX positively regulates FGFR3 expression in U2OS and normal human dermal fibroblast cells
To identify novel SHOX target genes, we transfected normal human dermal fibroblast (NHDF) and U2OS cells with wild-type pcDNA4/TO-SHOX or mutant pcDNA4/ TO-SHOX-Y141D. SHOX-Y141D was originally found in ISS patients and encodes a SHOX protein variant with the amino acid change Y141D, which fundamentally impairs SHOX key functions (25) . We performed microarray analyses of RNA samples from different time points after transfection and compared the gene expression of cells transfected with either the wild-type SHOX or the Y141D variant (S. Bender, E. Decker, M. Baas, R. Roeth, C. Durand, B. Weiss, A. Arens, B. Korn, H. Zentgraf and G. Rappold, submitted for publication). One of the genes with the strongest up-regulation upon SHOX overexpression in both cell systems was FGFR3, which is known to play an important role during limb development. We found a clear up-regulation of FGFR3 12 and 24 h after SHOX transfection in U2OS as well as in NHDF cells. To validate these findings, quantitative real-time polymerase chain reaction (qRT-PCR) was carried out (Fig. 1) . We could confirm the initial data by detecting a strong, SHOX-dependent up-regulation of FGFR3 expression in both cell systems that was not present after transfection with the SHOX-Y141D variant. The strongest up-regulation of 17-and 28-fold in U2OS and NHDF, respectively, was seen 24 h after transfection (Fig. 1A and B) . SHOX2, a closely related SHOX paralog (1, 26) , did not alter FGFR3 expression in control experiments (Supplementary Material, Fig. S1A ).
We also tested the effect of siRNA-mediated knockdown of SHOX on FGFR3. NHDF cells, which showed a stronger up-regulation compared with U2OS upon SHOX overexpression, were transfected with one of the two different SHOX siRNAs or control siRNA, and gene expression was measured after 24 and 48 h using qRT-PCR. The reduction in SHOX expression resulted in a decrease of 50% of FGFR3 expression ( Fig. 1C and D) . In contrast, siRNA-mediated knockdown of SHOX2 had no effect on FGFR3 expression (Supplementary Material, Fig. S1B -D) .
SHOX can bind to and regulate the extended promoter region of FGFR3
To determine genome-specific elements that are recognized by SHOX, we performed chromatin immunoprecipitationsequencing (ChIP-Seq) experiments on human NHDF cells as well as on chMM cultures, a model system for endochondral ossification. Both approaches in human and chicken revealed sequences that map to the vicinity of the FGFR3/ Fgfr3 gene locus. In chMM cells, sequencing data of Shoxbound DNA identified four putative response elements located up to 10 kb upstream or downstream of the Fgfr3 transcriptional start site (TSS) (Supplementary Material, Table S1 ; NCBI Sequence Read Archive, Accession nr. SRA024982). The ChIP-Seq experiment in human NHDF also showed an enrichment of the region 23424 to 23364 bp upstream of the FGFR3 TSS (Bender et al., submitted for publication). Sequence alignment revealed no direct overlap of putative chicken Shox-binding sites and the human SHOX-binding site. In subsequent experiments, we focused on the site that has been found in NHDF cells in order to further evaluate the potential regulatory effect in human.
By performing EMSA (electrophoretic mobility shift assay) experiments, we could show a binding of purified glutathione S-transferase (GST)-tagged SHOX protein to the identified 60 bp region subsequently termed 'ChIP-Seq complete', suggesting that this region might be involved in the SHOXdependent regulation of FGFR3. To narrow down the precise binding element, we subdivided the sequence into three overlapping 32 bp long fragments ('CSeq A', 'CSeq B' and 'CSeq C') and tested each by EMSA for SHOX binding. 'CSeq A' was not bound by SHOX; however, both 'CSeq B' and 'CSeq C', spanning the middle and 3 ′ area of 'ChIP-Seq complete', showed a shift when incubated with SHOX protein. This finding demonstrates that an in vitro SHOX-binding site resides in the overlapping sequence of both 'CSeq B' and 'CSeq C' ( Fig. 2A and B) , which encompasses short AT palindromes and AT-rich sequences similar to the ones that have been previously characterized as SHOX target sequences (27) . If these AT motifs are required for Human Molecular Genetics, 2011, Vol. 20, No. 8 1525 correct SHOX binding, then replacing them should abolish their binding potential. Two different 'CSeq B' oligonucleotides containing three mutated nucleotides, each destroying an AT motif, were no longer able to bind to SHOX protein, thus confirming the necessity of these sequences for SHOX binding ( Fig. 2A and C) . In addition, we used luciferase reporter gene assays to analyze the regulatory potential of the ChIP-Seq region and the extended FGFR3 promoter after SHOX overexpression in U2OS cells. For this purpose, we cloned different FGFR3 upstream sequences in front of the firefly luciferase gene and compared the effect of SHOX and SHOX-Y141D transfection on firefly luciferase activity. As a control for transfection efficiency and cell number, firefly luciferase activity was normalized to the activity of the co-transfected Renilla luciferase.
The construct FGFR3 23365/+550 bp, which encompasses a region of 3365 bp upstream and 550 bp downstream of the FGFR3 TSS, showed a more than 60-fold up-regulation of luciferase activity in U2OS upon SHOX transfection compared with mutant SHOX-Y141D or with SHOX2. To our surprise, analysis of the luciferase activity for the construct FGFR3 23453/+550 bp, which is identical to the initial sequence except for the inclusion of the ChIP-Seq area, showed only a 25-fold up-regulation (Fig. 3) . This decrease in transactivation potential compared with the 23365/+550 bp construct might be caused by SHOX binding to the region identified in ChIP-Seq or by other so far unknown factors. Despite this negative influence on luciferase activity displayed by the ChIP-Seq sequence, the overall effect of SHOX on the extended FGFR3 promoter was clearly positive. To explain this observation, we analyzed 5 kb upstream and 550 bp downstream of the FGFR3 TSS for additional potential SHOX-binding sites that might be responsible for this positive regulation seen in qRT-PCR and the luciferase constructs. The extended FGFR3 promoter is very GC-rich, and a search for AT palindromes (ATTA or TAAT) revealed only 10 additional palindromes clustered into five new putative SHOX-binding sites. All of them showed positive results in EMSA experiments (Fig. 4) . Subsequent ChIP experiments in U2OS showed an enrichment of all tested binding sites in SHOX-immunoprecipitated DNA, thus confirming the EMSA results (Supplementary Material, Fig. S2 ). We cloned the sequence of ChIP-Seq complete as well as three of the five additional putative binding sites (61-90 bp length) into pGL3-Promoter and measured the luciferase activity. Despite their ability to bind SHOX, none of these short binding sites alone had any effect on the activity upon SHOX transfection. Table S1 ). The corresponding regions feature AT palindromes in both human and chicken, in contrast to the human binding site 23424 to 23364 bp whose AT palindromes are not conserved in chicken (Fig. 4) .
To further analyze the cell-specific role of the putative regulatory regions in U2OS and NHDF, we compared the effect of SHOX overexpression on FGFR3 mRNA expression (by RT-PCR) and on reporter gene activity of the construct FGFR3 23365/+550 bp (luciferase) in both cell types. To ensure identical conditions, cells were transfected in parallel for both analyses with pGL3-Basic FGFR3 23365/+550 bp, pRL-TK and either wild-type SHOX or the SHOX-Y141D variant. In both cell types, a SHOX-dependent increase in FGFR3 expression was detected by RT-PCR, with the effect being twice as strong in U2OS compared with NHDF. In contrast, the increase in the reporter gene activity of FGFR3 23365/+550 bp was 10-fold higher in U2OS than in NHDF, thus showing a much stronger differential between U2OS and NHDF than the 2-fold differential of SHOXdependent FGFR3 mRNA increase detected by RT-PCR results (data not shown). This specific impact of SHOX on total FGFR3 mRNA expression compared with reporter gene activity of a defined FGFR3 upstream region in two different cell systems suggests the existence of cell-specific regulatory regions and/or factors in NHDF and U2OS that influence FGFR3 expression.
In conclusion, by using luciferase reporter gene assays, SHOX was shown to strongly activate the extended FGFR3 promoter. Inclusion of a short SHOX-binding site identified by ChIP-Seq in NHDF reduced this effect. EMSA and ChIP experiments carried out in human U2OS cells further confirmed SHOX binding to additional sequences upstream of FGFR3, but none of these sites alone seems sufficient to regulate reporter gene expression.
Shox negatively regulates Fgfr3 expression in chMM cultures
To evaluate the regulatory role of Shox on Fgfr3 expression during limb development, we used chMM cultures, a model system for chondrogenesis and endochondral ossification (23, 24) . Mesenchymal cells derived from limb tissue from chicken of embryonic day 4.5 were cultured as high-density micromass cultures in which cells spontaneously differentiate into chondrocytes, thereby mimicking the sequential processes of endochondral ossification. Treatment with RCAS(BP), a replication-competent retroviral vector system, enables the overexpression of a gene of interest in chicken tissue (28) (29) (30) . In our study, isolated chicken cells were infected with RCAS(BP)-SHOX (encoding N-terminal 3× FLAG-tagged chicken Shox), RCAS(BP)-green fluorescent protein (GFP) or were left uninfected.
Whole-mount in situ hybridization (ISH) for Shox and Fgfr3 were carried out at days 3 and 6 of differentiation and showed a strong expression of Shox in all RCAS(BP)-SHOX-treated cells (data not shown), thus confirming a good infection efficiency. ISHs revealed a reduced Fgfr3 expression upon Shox infection in two independent experiments (Fig. 5A) .
To quantify this decrease, we isolated RNA from day 3, 6, 9 and 12 cultures and determined the gene expression levels by qRT-PCR. Shox expression was strongly increased upon RCAS(BP)-SHOX infection, but remained stable in the control samples during differentiation (Fig. 5B) . At all time points, we detected a 2 -3-fold lower Fgfr3 expression in the RCAS(BP)-SHOX-infected cultures compared with controls (Fig. 5C ). These negative effects of Shox on Fgfr3 expression in chMM experiments are in contrast to the positive effects in U2OS and NHDF cells (Fig. 1) .
ISH of Shox and Fgfr3 during chicken limb development show almost mutually exclusive expression patterns
We carried out whole-mount ISH and ISH on cryosections to compare the expression patterns of Shox and Fgfr3 in the developing chick limb. Whole-mount analysis demonstrated that Shox expression starts at day 3.25 in the early wing and leg buds (Fig. 6A) . At this developmental stage, Fgfr3 is broadly expressed, in particular in neuronal tissues. Interestingly, the expression is comparatively weak in the early limb buds (Fig. 6B) . At later stages, both genes are expressed in the developing limbs; however, the expression patterns appear mutually exclusive (Fig. 6C-F) . Due to the restricted penetrance of the probes into the tissue, the expression patterns seen in whole-mount ISHs represent predominantly the expression at the body surface. To analyze the expression during bone formation in more detail, we carried out ISH on cryosections of embryonic day 6 chicken limbs. Strong Shox expression was detected in the ectoderm as well as in the periphery of the condensed, differentiating chondrocytes in the region of the perichondrium. Low expression was present within the chondrocytes of the future bone region (Fig. 6G,  I and K). In contrast, Fgfr3 expression was very strong in all types of chondrocytes, but absent from other limb tissues such as the perichondrium (Fig. 6H, J and L) . Thus, both ISH approaches demonstrated mainly mutually exclusive expression patterns of Shox and Fgfr3 in the developing chicken limb.
DISCUSSION
To increase our knowledge of the role of SHOX during limb development, we aimed to identify and characterize transcriptional target genes. Using different experimental approaches, we could show that SHOX is able to regulate the expression of FGFR3 in different cell types and in chMM cultures. Overexpression of SHOX in the osteosarcoma cell line U2OS as well as in the primary fibroblasts NHDF increased FGFR3 expression, whereas knockdown of SHOX in NHDF led to reduced FGFR3 expression levels. Thus, in these cell types, SHOX has a positive effect on FGFR3. In contrast, overexpression experiments in chMM cultures revealed a repressive effect of Shox on Fgfr3 expression, as demonstrated by ISHs and qRT-PCR.
Luciferase reporter gene assays showed a positive regulatory effect of SHOX on the extended FGFR3 promoter, whereas the inclusion of a SHOX-binding site identified by ChIP-Seq reduced this activating effect. Data from further ChIP and EMSA experiments indicate that, in addition to the ChIP-Seq region, SHOX is able to bind at least five other sequences spread over a region of 3 kb in the extended promoter, offering a possible explanation for the observed reporter gene up-regulation. Gotea et al. (31) recently demonstrated that a clustering of multiple target sites for individual transcription factors in promoter and enhancer sequences represents an important mechanism of gene regulation efficiency. These findings might explain the existence of multiple SHOXbinding sites in the FGFR3 extended promoter as a means to fine-tune FGFR3 expression levels.
All EMSA-binding sites contain AT palindromes, similar to the ones that have been identified as SHOX consensus sequences (27) . Mutations of the respective palindromes abolished SHOX binding, indicating a functional relevance of these elements for correct SHOX/DNA interaction. However, the regulatory relevance of this SHOX binding is currently not clear. Four characterized short SHOX-binding sequences alone were not sufficient to regulate reporter gene expression. This may be due to the fact that one or multiple cofactors cooperate with SHOX and bind to distinct DNA sequences not included in these short constructs. Interaction of SHOX with different cofactors is likely since most The increase in luciferase activity upon SHOX compared with SHOX-Y141D overexpression is .60-fold for the sequence 23365/+550 bp. Inclusion of ChIP-Seq complete (-3453/+550 bp) leads to a 25-fold increase, and ChIP-Seq complete alone has no effect on the luciferase activity. ex1, exon 1; intr1, intron 1.
homeodomain transcription factors require interaction partners to exert their highly specific functions. Consistent with this assumption, we could show that a defined FGFR3 upstream region has a different impact in SHOX-dependent transcriptional regulation in NHDF and U2OS, suggesting the presence of individual regulatory regions with different responses to cell-specific cofactors. Thus, we speculate that, depending on the cellular environment, the availability of cofactors and/or the specific binding site, SHOX can act as either an activator or a repressor on the expression of FGFR3. Tissuespecific, cofactor-dependent opposite regulation of a gene by a particular transcription factor has been reported before. HOX proteins, for example, can switch from activators to repressors of target gene expression depending on the activation of different cofactors and signaling pathways in different tissues (32, 33) . Zarnegar et al. (34) could show that RUNX1 together with different cofactors is able to silence or activate the expression of PU.1. Pu.1 in turn is capable of activating or silencing the expression of TAL-1 depending on different tissue-specific cofactors and binding sites (35) . To date, no cofactors for SHOX have been described, which impedes the understanding of the potential SHOX-dependent regulatory mechanism responsible for FGFR3 expression.
FGFR3 regulation in general is not well understood. Previous studies have identified a small number of factors able to regulate FGFR3, e.g. Sp1 (36), Prox1 (37) Bmp2 (38), Ap2d (39) and p63/p73 (40) . All of the identified corresponding binding sites are located in the core promoter close to the FGFR3 TSS. Furthermore, it was shown for Bmp2 and Ap2d that modifications of the FGFR3 core promoter structure are involved in changes in FGFR3 expression (38, 39) . To our knowledge, this study is the first to identify FGFR3 regulatory elements in a distance up to 5 kb from the TSS.
Since we were primarily interested in transcriptional target genes of SHOX, we focused on the transcriptional regulation of FGFR3 and left the functional output out of consideration. Thus, in subsequent experiments, it would be interesting to analyze the influence of the identified transcriptional regulator SHOX on FGFR3 phosphorylation and downstream signaling. Our results suggest that transcriptional regulation of FGFR3 might play a so far underestimated role in the development of short stature.
FGFR3 has a critical role during limb development. It is known that FGFR3 predominantly inhibits proliferation and promotes the differentiation of chondrocytes, thus being a negative regulator of post-natal bone growth (41) . Interestingly, cells of other origins and developmental stages as well as a number of tumor cells show increased proliferation after exposure to FGFR3 or FGFR3 gain-of-function variants (42) (43) (44) (45) . Mutations of FGFR3 in humans lead to different forms of syndromic skeletal malformation and short stature, including achondroplasia, the most frequent form of human short stature with disproportionately short limbs, as well as hypochondrodysplasia and thanatophoric dysplasia type I and II (46, 47) . A characteristic clinical feature found in patients is the disproportionate shortening of the long bones of the limbs, especially of the proximal (rhizomelic) bones in the upper arm and leg. All the different FGFR3-related syndromes are caused by gain-of-function mutations; the stronger the activity of the mutated FGF3 receptor, the more pronounced the corresponding clinical manifestation (48) . On the contrary, a dominant negative loss-of-function mutation in humans is associated with tall stature (49) , and Fgfr3 knockout mice exhibit skeletal overgrowth (50, 51) . SHOX, on the other hand, has a positive effect on bone length (6, 21) . Loss-of-function mutations lead to mesomelic short stature, where especially the forearms and lower legs are affected.
We have shown in several in vitro and in vivo systems that SHOX represents a strong regulator of FGFR3. A positive regulation of FGFR3 by SHOX, as detected in U2OS and NHDF cells, may not be compatible with respect to the clinical manifestations in the limbs of affected patients. In contrast, a repressive effect of Shox on FGFR3 expression as observed in chMM cultures, which represents a more suitable model system for limb development, can much better explain the underlying mechanisms of the human phenotypes. A negative regulation is also consistent with the mutually exclusive expression patterns of Shox and Fgfr3 detected in developing chicken limbs. The observed FGFR3 repression might be particularly relevant in mesomelic segments where SHOX is predominantly active (1) . In healthy individuals, SHOXdependent repression would generally result in a lower expression of FGFR3 in the mesomelic segments compared with the rhizomelic segments where SHOX expression is much weaker. Consequently, SHOX deficiency would create a relatively increased FGFR3 expression in ulna and radius as well as in tibia and fibula, thereby accelerating a fusion of the growth plates and causing a relative shortening of the respective bones. The effect on the rhizomelic segments should be less pronounced, which is consistent with the human phenotypes (14, 52) . FGFR3 gain-of-function mutations, on the other hand, would have a stronger effect on the upper arm and leg, since FGFR3 is not targeted by SHOX in that part of the limbs and therefore expressed at higher levels than in the mesomelic segments. This overrepresentation of FGFR3 would result in an earlier growth plate closure of humerus and femur compared with the lower limb segments, which is in line with the rhizomelic short stature found in achondroplasia patients (46) . In addition, we could show that the highly related homeobox gene SHOX2, which is expressed predominantly in the rhizomelic segments (1), is not able to regulate FGFR3. Thus, the given hypothesis provides a possible genetic mechanism explaining the two different human phenotypes.
Even though the SHOX protein was detected in radial and tibial growth plates by immunohistochemistry (3 -5) , quantitative data from growth plates of mesomelic and rhizomelic segments are still missing. Furthermore, the analysis of FGFR3 expression in growth plates from different limb segments would provide more insight into our hypothesized mechanism. Due to a limited availability of growth plate samples from healthy individuals, the characterization of FGFR3 in human growth plates is impeded. 
RCAS(BP)-SHOX (B). Fgfr3 expression is negatively regulated by RCAS(BP)-SHOX infection compared with RCAS(BP)-GFP and untreated cells (C).
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In summary, we present a link of the molecular and genetic regulatory pathways responsible for short stature in patients with SHOX deficiency or FGFR3 gain-of-function mutations.
MATERIALS AND METHODS
Cell culture and transfection
U2OS cells (human osteosarcoma cells, ATCC) and NHDF cells (PromoCell) were cultured in DMEM (Dulbecco's modified Eagle's medium; Gibco) containing 10% FBS (fetal bovine serum gold; PAA) and penicillin/streptomycin (Gibco) at 378C, 5% CO 2 and 95% humidity. For overexpression experiments, 1 -2 × 10 6 cells were transfected with 1 mg of pcDNA4/TO-SHOX (27) , pcDNA4/TO-SHOX-Y141D (25) or pDEST31-SHOX2a (subcloned using the Gateway system, Invitrogen). SHOX-Y141D encodes a mutant SHOX protein whose amino acid change Y141D renders it functionally defective. SHOX2 is a closely related SHOX paralog (26) . Transfections were carried out using the Cell Line Nucleofector Kit V (Lonza) and the Human Dermal Fibroblast Nucleofector Kit (Lonza) for U2OS and NHDF, respectively, or Lipofectamine2000 Transfection reagent (Invitrogen) for both cell lines according to the manufacturer's instructions. For knockdown experiments, NHDF cells were seeded into 6-well plates and transfected with 40 pmol/well of SHOX siRNA1 (#HSS109735, Invitrogen), siRNA2 (#HSS109737, Invitrogen) or control siRNA (Invitrogen), using Lipofectamine2000 Transfection reagent (Invitrogen). In control experiments, NHDF cells were transfected with either SHOX2 siRNA1 (#HSS143929, Invitrogen), siRNA2 (#HSS143931, Invitrogen) or control siRNA (Invitrogen). Six hours after transfection, medium was changed. Cells were harvested after 6, 12, 24 and 48 h (overexpression) or 24 and 48 h (knockdown) for microarray and/or qRT-PCR experiments.
Microarray
Total RNA from NHDF and U2OS cells was isolated using the Illustra RNAspin Isolation Kit (GE Healthcare) according to the manufacturer's instructions. RNA quality and quantity were checked by the NanoDrop spectrophotometer (NanoDrop Technologies). For hybridization on Illumina Human Sentrix-8 BeadChip arrays, biotin-labeled cRNA was prepared according to Illumina's recommended sample labeling procedure: 250 ng of total RNA was used for cDNA synthesis, followed by an in vitro transcription to generate biotin-labeled cRNA using the MessageAmp II aRNA Amplification Kit (Ambion). Hybridization was performed at 588C in GEX-HCB buffer (Illumina) at a concentration of 100 ng cRNA/ml in a wet chamber for 20 h. Microarrays were washed twice in E1BC buffer (Illumina) at room temperature (RT) for 5 min. After blocking for 5 min in 4 ml of 1% (w/v) Blocker Casein in phosphate buffered saline (PBS) (Gibco), array signals were developed by 10 min incubation in 2 ml of 1 mg/ml Cy3-streptavidin solution (Amersham Biosciences) Figure 6 . Expression of Shox and Fgfr3 in chicken embryos. Whole-mount ISH of chicken embryos at day 3.25 (A and B), day 5 (C and D) and day 7 (E and F). Shox and Fgfr3 are expressed in the developing limbs in almost mutually exclusive expression patterns, as indicated by arrows. ISH of transversal sections of the lower leg (G and H) and sagittal sections through the foot (I-L) of day 6 chicken embryos. Shox is expressed strongly in the perichondrium and the ectoderm and weaker in mesenchyme and chondrocytes. and 1% blocking solution. After a final wash in E1BC, the arrays were dried and scanned, using a Beadstation array scanner (Illumina). Data were extracted for all beads individually, and outliers were removed if .2.5 median absolute deviation. All remaining data points were used for the calculation of the mean average signal and standard deviation for each probe. For each analyzed time point (6, 12 and 24 h), we compared the signal intensity of normalized gene expression of SHOX-transfected samples with SHOX-Y141D-transfected controls.
cDNA synthesis and qRT-PCR Total RNA was extracted using the Illustra RNAspin Isolation Kit (GE Healthcare) according to the manufacturer's instructions. One microgram of isolated RNA was transcribed into cDNA with SuperScript III reverse transcriptase (Invitrogen). qRT-PCR was carried out using the Applied Biosystems 7500 Real-Time PCR System and Absolute SYBR Green QRT-PCR Mix (Abgene). Each sample was run in duplicate. Relative levels of mRNA expression were calculated according to the delta -delta C t method (53) by normalization to mRNA expression of three housekeeping genes [peptidylprolyl isomerase A (PPIA), succinate dehydrogenase complex subunit A (SDHA) and hypoxanthine phosphoribosyltransferase 1 (HPRT1) for human samples; ADP-ribosylation factor 1 (Arf1), hexose-6-phosphate dehydrogenase (H6pd) and Sdha for chicken samples]. Figures show one representative experiment of at least two independent biological replicates. All primer sequences are given in Table 1 .
ChIP and ChIP-Seq in human cells
A total of 1 × 10 7 cells (U2OS or NHDF) were transfected with pcDNA4/TO-SHOX-FLAG (N-terminal FLAG tag, cloned into HindIII/BamHI-digested pcDNA4/TO). Twentyfour to 48 h post-transfection, ChIP and ChIP-Seq were carried out as described previously (54) using anti-FLAG monoclonal antibody (Sigma, F1804). Primer sequences for ChIP are listed in Supplementary Material, Table S2 .
ChIP-Seq in chicken micromass
For ChIP-Seq, day 9 chMM culture cells (see below) were infected with RCAS(BP) expressing N-terminal 3× FLAGtagged chicken Shox or an empty RCAS(BP) virus as a control.
ChIP was performed as described previously (55) 
Luciferase assay
Different regions of the extended FGFR3 promoter were cloned into the pGL3-Basic or the pGL3-Promoter vector (Promega) upstream of a firefly luciferase. For luciferase reporter gene assays, U2OS cells were seeded into 24-well plates and transfected with 200 ng of firefly reporter construct, 100 ng of pRL-TK (Promega), which expresses Renilla luciferase as a transfection control, and 200 ng of pcDNA4/ TO-SHOX or -SHOX-Y141D per well. In control experiments, exemplary firefly reporter constructs were also tested in NHDF cells. Luciferase activity was measured in triplicates 24 h after transfection using the Dual-Luciferase Assay Kit (Promega) according to the manufacturer's protocol. Figure 3 shows the pooled data of at least three independent biological replicates per construct.
Clones were generated with the following PCR primers: 23365 bp For ATGCTCCTGCCCTTTGACCTAAC, +550 bp Rev GAATAACAACAGCGGGAATCGTG (clone FGFR3 23365/+550 bp); 23453 bp For CAGAGTGGGCAGCAA CTCCT, +550 bp Rev GAATAACAACAGCGGGAATCGTG (clone FGFR3 23453/+550 bp). The construct FGFR3 23429/23358 bp was generated using the DNA oligonucleotides GGCCCGGGGGTGGCCGTGGCGGCACTAGGACCC TTTTGAAACCAATTTGGCAAAATTAGCGGCACCACGG AAATGCTCC (For) and GGCCCGGGGGAGCATTTCC GTGGTGCCGCTAATTTTGCCAAATTGGTTTCAAAAGG GTCCTAGTGCCGCCACGGCCACC (Rev). The names of the FGFR3/luciferase-constructs refer to the distances to the FGFR3 TSS (NM_000142).
Electrophoretic mobility shift assay
EMSAs were performed as reported previously (25) . Briefly, 1 ml of 32 P-labeled oligonucleotides was incubated with purified, bacterially expressed recombinant GST SHOX proteins for 10 min in a buffer containing 15 mM N-(2-hydroxyethyl)piperazine-N-(2-ethanesulfonicacid) pH 7.5, 60 mM NaCl, 1 mM ethylenediaminetetraacetate (EDTA), 0.5 mM dithiothreitol, 0.05% Nonidet P-40, 7.5% glycerol, 4 mM spermidine, 0.25 mg/ml bovine serum albumin (BSA) and 0.5 mg poly(dI-dC). Samples were loaded on native 5% polyacrylamide gels and electrophoresed in 0.25×tris/borate/EDTA buffer at 100 V for 1 h. Gels were dried and exposed 1 h for autoradiography.
Generation of riboprobes
Riboprobes were generated and digoxigenin-labeled by in vitro transcription (DIG RNA Labeling Mix, Roche) of PCR products amplified out of chicken cDNA, using the following primers: chiSHOX_1_For GAGCTTGGGAACTCC-GATT and chiSHOX_2_Rev TTCAGACAGTCCCAGC CTCT for Shox (length of probe: 333 bp); chFGFR3 ISH For2 AGCTGATTTTGGCCTTGCTA and chFGFR3 ISH
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Rev2 GAACACTGCCTGTCTGTCCA for Fgfr3 (length of probe: 582 bp).
Chicken ISH
Whole-mount ISHs of chicken embryos were performed as described previously (19) . For sections, day 6 chicken embryos were fixed in 4% paraformaldehyde (PFA)/11% sucrose (w/v in PBS), dehydrated in 25% sucrose (w/v in PBS) and embedded in tissue freezing medium (Jung). Using a cryostat microtome (Leica), 12 mm sections of the developing limbs were generated. Serial sections were used for ISHs. Sections were fixed in 4% PFA in PBS at RT for 20 min, washed twice in PBS for 5 min and treated with 5 mg/ml of proteinase K/PBS for 6 min. Slides were then washed in PBS (5 min), post-fixed in 4% PFA/PBS for 15 min, rinsed with H 2 O and then acetylated in 0.1 M triethanolamine HCl, pH 8.0, with 0.25% acetic anhydride for 10 min. Washing in PBS was followed by prehybridizing the samples with hybridization buffer (50% formamide, 5× saline-sodium citrate buffer (SSC), 0.3 mg/ml Yeast tRNA, 0.1 mg/ml heparin, 0.1% Tween 20, 1× Denhardt's solution, 5 M EDTA) for 3 h. Slides were then incubated at 688C overnight with fresh hybridization buffer containing 1 ng/ml of specific digoxigenin-labeled antisense riboprobe. After hybridization, samples were washed in 2× SSC at 60-658C for 15 min, followed by a washing step in 2× SSC at RT. To digest singlestranded non-hybridized RNA, samples were incubated with 10 mg/ml RNaseA and 1 U/ml RNaseT1 in 2× SSC at 378C for 30-45 min, followed by multiple washing steps [2× in 2× SSC at RT for 5 min, 2× in 0.2× SSC at 60-658C for 30 min, 1× in 0.2× SSC at RT for 2 min and 2× in phosphate buffered saline with BSA and triton-x (PBT) (1× PBS, 2 mg/ml BSA, 0.1% Triton X-100) at RT for 20 min]. Blocking was carried out by incubating the slides in PBT + 10% heat-inactivated horse serum for 1 h at RT, followed by an overnight incubation with an antidigoxigenin antibody (Anti-Digoxigenin-AP, Fab fragments, 1:1000; Roche (Gibco) and penicillin/streptomycin (Gibco)], the resulting suspension was passed through a 40 mm nylon filter (BD) to remove cell aggregates. Cells were counted, and the suspension was adjusted with chMM medium to a concentration of 2 × 10 7 cells/ml. Aliquots of this suspension were treated with 50 ml of RCAS virus solution (5 × 10 7 virus particles/ml) RCAS(BP)-SHOX or RCAS(BP)-GFP or 50 ml of virus-free medium. Drops of 10 ml were seeded into 24-well plates and incubated for 2 h at 378C, 5% CO 2 and 95% humidity. Subsequently, 2 ml of chMM medium were added and cells were cultivated, forming round cultures which were harvested after 3, 6, 9 and 12 days with a medium change every 2 days. For qRT-PCR, RNA was isolated and processed as described above. For ISHs, cultures were fixed with 4% PFA for 30-60 min and subjected to whole-mount ISH as described above with probes for Shox or Fgfr3. 
